Autolus Therapeutics (AUTL)
1.44
-0.03 (2.04%)
Upcoming Events
Latest Headlines
Form 4 Autolus Therapeutics For: Jun 29 Filed by: YOUNG WILLIAM D
July 1, 2026 4:21 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: Rao Madduri Ravin
July 1, 2026 4:19 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: Richardson Ryan
July 1, 2026 4:17 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: Leiderman Elisabeth
July 1, 2026 4:16 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: Iannone Robert
July 1, 2026 4:13 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: BUTITTA CYNTHIA M
July 1, 2026 4:11 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: Bain Linda
July 1, 2026 4:09 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: Azelby Robert
July 1, 2026 4:07 PM - SEC Filing
Form 4 Autolus Therapeutics For: Jun 29 Filed by: BONNEY MICHAEL W
July 1, 2026 4:05 PM - SEC Filing
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026 4:05 PM - StreetInsider
Form 8-K Autolus Therapeutics For: Jun 29
June 29, 2026 4:03 PM - SEC Filing
Autolus Therapeutics to Participate in Upcoming Investor Conference
June 25, 2026 7:00 AM - StreetInsider
Autolus Therapeutics Receives Prix Galien UK Award
June 12, 2026 4:00 AM - StreetInsider
Form 8-K Autolus Therapeutics For: Jun 05
June 9, 2026 7:31 AM - SEC Filing
Autolus Therapeutics to Participate in Upcoming Investor Conferences
May 27, 2026 7:00 AM - StreetInsider
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
May 21, 2026 5:10 PM - Globe NewsWire
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 19, 2026 6:30 AM - PR NewsWire
Byondis forms scientific advisory board with oncology experts
May 18, 2026 7:00 AM - StreetInsider
Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development
May 18, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: MAK Capital Fund LP
May 15, 2026 3:05 PM - SEC Filing
Form SCHEDULE 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC
May 15, 2026 11:06 AM - SEC Filing
Autolus Therapeutics plc (AUTL) PT Lowered to $5.40 at Goldman Sachs
May 15, 2026 6:29 AM - StreetInsider
Form 10-Q Autolus Therapeutics For: Mar 31
May 14, 2026 4:32 PM - SEC Filing
Form 8-K Autolus Therapeutics For: May 14
May 14, 2026 7:54 AM - SEC Filing
Autolus Therapeutics (AUTL) Misses Q1 EPS by 2c, Misses on Revenue; Offers FY26 Revenue Guidance
May 14, 2026 7:08 AM - StreetInsider
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 14, 2026 7:00 AM - Globe NewsWire
Form EFFECT Autolus Therapeutics
May 6, 2026 6:08 AM - SEC Filing
Form EFFECT Autolus Therapeutics
May 6, 2026 6:08 AM - SEC Filing
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
May 5, 2026 7:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Autolus Therapeutics plc (AUTL)
April 30, 2026 6:55 AM - StreetInsider
Form 8-K Autolus Therapeutics For: Apr 29
April 29, 2026 5:29 PM - SEC Filing
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
April 29, 2026 4:05 PM - StreetInsider
Prilenia names Dr. Elisabeth Leiderman as chief financial officer
April 28, 2026 8:00 AM - StreetInsider
Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer
April 28, 2026 8:00 AM - BizWire
AGC Biologics Wins 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance
April 27, 2026 11:59 AM - Globe NewsWire
Full Article List
